Vistagen Therapeutics (VTGN) Retained Earnings (2017 - 2025)
Historic Retained Earnings for Vistagen Therapeutics (VTGN) over the last 13 years, with Q4 2025 value amounting to -$461.0 million.
- Vistagen Therapeutics' Retained Earnings fell 1701.6% to -$461.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$461.0 million, marking a year-over-year decrease of 1701.6%. This contributed to the annual value of -$407.6 million for FY2025, which is 1443.46% down from last year.
- As of Q4 2025, Vistagen Therapeutics' Retained Earnings stood at -$461.0 million, which was down 1701.6% from -$442.1 million recorded in Q3 2025.
- Vistagen Therapeutics' Retained Earnings' 5-year high stood at -$219.8 million during Q1 2021, with a 5-year trough of -$461.0 million in Q4 2025.
- Over the past 5 years, Vistagen Therapeutics' median Retained Earnings value was -$337.1 million (recorded in 2023), while the average stood at -$334.6 million.
- Its Retained Earnings has fluctuated over the past 5 years, first tumbled by 888.24% in 2021, then crashed by 2683.03% in 2022.
- Quarter analysis of 5 years shows Vistagen Therapeutics' Retained Earnings stood at -$250.9 million in 2021, then fell by 25.39% to -$314.6 million in 2022, then decreased by 10.19% to -$346.7 million in 2023, then decreased by 13.64% to -$394.0 million in 2024, then decreased by 17.02% to -$461.0 million in 2025.
- Its Retained Earnings was -$461.0 million in Q4 2025, compared to -$442.1 million in Q3 2025 and -$422.7 million in Q2 2025.